

ORION PHARMA LIMITED AND ITS SUBSIDIARIES
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
AS AT AND FOR THREE MONTH PERIOD ENDED 30 SEPTEMBER 2021
(FIRST QUARTER)

ORION PHARMA LIMITED AND ITS SUBSIDIARIES
Condensed Consolidated Statement of Financial Position (Unaudited)
As at 30 September 2021

Particulars		Amount In BDT	
		30-Sep-21	30-Jun-21
Assets			
Non-Current Assets		27,323,992,381	26,110,018,103
Property, Plant and Equipment	6	14,137,420,725	14,219,821,108
Right of use Assets	7	44,368,373	50,811,429
Construction Work in Progress	8	6,777,605,617	5,584,939,176
Investment in Associates	10	403,573,000	303,455,000
Other Investments	11	5,961,024,665	5,950,991,390
Current Assets		16,180,396,683	16,223,065,351
Inventories	12	1,242,523,043	1,364,387,400
Trade and Other Receivables	13	12,794,041,634	12,401,457,500
Advances, Deposits & Prepayments	14	1,782,927,288	2,018,609,949
Fixed Deposit with Banks	15	28,378,036	23,616,354
Cash and Cash Equivalents	16	332,526,681	414,994,148
Total Assets		43,504,389,063	42,333,083,454
Shareholders' Equity and Liabilities			
Shareholders' Equity		18,848,150,654	18,662,734,883
Share Capital	17	2,340,000,000	2,340,000,000
Share Premium		8,016,892,026	8,016,892,026
Reserves	18	2,017,427,797	1,904,852,372
Retained Earnings	19	6,473,830,832	6,400,990,484
Non - Controlling Interest	20	1,411,744,964	1,411,671,307
Total Equity		20,259,895,618	20,074,406,190
Non-Current Liabilities		17,153,721,165	16,251,126,042
Provision for Decommissioning of Assets		143,405,563	143,405,563
Long Term Loan	21	16,834,442,023	15,929,537,566
Lease Obligation	22	32,327,660	39,898,633
Deferred Tax Liability	23	143,545,918	138,284,281
Current Liabilities		6,090,772,280	6,007,551,222
Current portion of Long Term loan	21.1	393,493,077	274,326,280
Current Portion of Lease Obligation	22.1	34,212,112	36,415,462
Short term loans	24	561,779,563	564,317,167
Trade and Other Payables	25	4,505,299,621	4,601,266,353
Employee Benefits	26	103,492,019	97,229,950
Accrued Expenses	27	492,495,888	433,996,009
Total Equity & Liabilities		43,504,389,063	42,333,083,454
Number of Shares Used to Compute NAV		234,000,000	234,000,000
Net Asset Value (NAV) Including Revaluation Surplus	32	80.55	79.76
Net Asset Value (NAV) Excluding Revaluation Surplus		72.59	71.79

Sd/-
Sd/-
Sd/-
Sd/-
Sd/-

Chairman
Managing Director
Director
Chief Financial Officer
Company Secretary

ORION PHARMA LIMITED
Condensed Statement of Financial Position (Unaudited)
As at 30 September 2021

Particulars	Amount In BDT	
	30-Sep-21	30-Jun-21
Assets		
Non-Current Assets	18,090,411,871	16,851,710,644
Property, Plant and Equipment	6a 7,688,340,215	7,746,013,649
Right of use Assets	7 44,368,373	50,811,429
Construction Work in Progress	8 6,777,605,617	5,584,939,176
Investment in Subsidiaries	9 1,017,000,000	1,017,000,000
Investment in Associate	10 403,573,000	303,455,000
Other Investments	11a 2,159,524,665	2,149,491,390
Current Assets	9,779,754,902	9,810,320,511
Inventories	12a 330,533,014	344,345,275
Trade and Other Receivables	13a 7,786,653,784	7,563,464,801
Advances, Deposits & Prepayments	14a 1,462,286,295	1,678,287,378
Fixed Deposit with Banks	15 28,378,036	23,616,354
Cash and Cash Equivalents	16a 171,903,772	200,606,704
Total Assets	27,870,166,773	26,662,031,155
Shareholders' Equity and Liabilities		
Shareholders' Equity	12,622,483,348	12,412,193,719
Share Capital	17 2,340,000,000	2,340,000,000
Share Premium	8,016,892,026	8,016,892,026
Reserves	18a 1,649,756,753	1,536,805,467
Retained Earnings	19a 615,834,569	518,496,227
Non-current Liabilities	13,553,878,057	12,651,282,936
Long term loan	21a 13,378,004,479	12,473,100,022
Lease obligation	22 32,327,660	39,898,633
Deferred tax liability	23 143,545,918	138,284,281
Current Liabilities	1,693,805,368	1,598,554,500
Current portion long term loan	21a.1 393,493,077	274,326,280
Current portion of finance lease obligation	22.1 34,212,112	36,415,462
Short term loans	24 561,779,563	564,317,167
Trade and other payables	25a 305,663,560	359,221,873
Employee benefits	26a 34,140,917	28,113,432
Accrued expenses	27a 364,516,138	336,160,285
Total Equity & Liabilities	27,870,166,773	26,662,031,155
Number of Shares Used to Compute NAV	234,000,000	234,000,000
Net Asset Value (NAV) Including Revaluation Surplus	53.94	53.04
Net Asset Value (NAV) Excluding Revaluation Surplus	48.07	47.16

Sd/-
Chairman

Sd/-
Managing Director

Sd/-
Director

Sd/-
Chief Financial Officer

Sd/-
Company Secretary

ORION PHARMA LIMITED AND ITS SUBSIDIARIES
Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income (Unaudited)
For Three Month Period Ended 30 September 2021

Particulars	Amount In BDT		
	1 July 2021 to 30 September 2021	1 July 2020 to 30 September 2020	
Revenue from Net Sales	28	1,187,728,531	2,929,003,440
Cost of Goods Sold		(320,794,448)	(285,335,228)
Cost of Power Generation		(463,091,283)	(2,100,047,466)
Gross Profit		403,842,799	543,620,747
Operating Expenses		(253,250,824)	(222,646,994)
General & Administrative Expenses		(97,255,674)	(89,382,980)
Selling & Distribution Expenses		(155,995,150)	(133,264,013)
Profit from Operation		150,591,976	320,973,753
Financial Expenses	29	(49,013,336)	(78,025,428)
Non Operating Income/ (Loss)		432,941	539,912
Net Profit from Operation		102,011,581	243,488,238
Workers Profit Participation Fund		(6,262,069)	(11,594,678)
Net Profit before Tax		95,749,512	231,893,560
Income Tax		(28,572,950)	(25,427,598)
Current Tax (Expenses)/Income	30	(24,478,746)	(26,108,190)
Deferred Tax (Expenses)/Income		(4,094,204)	680,592
Net Profit after Tax		67,176,562	206,465,963
Share of Profit from Associate		3,189,600	2,082,100
Net Profit		70,366,163	208,548,063
Less: Non Controlling Interest (share of operating profit)		(73,657)	(17,454,993)
Net Profit after Tax before Other Comprehensive Income		70,292,505	191,093,070
Other Comprehensive Income		110,203,587	46,734,965
Fair Value Gain of Marketable Securities		10,012,620	4,812,893
Fair Value Gain on Investment in Associate		101,234,889	42,305,291
Share of Other Comprehensive Income		123,511	355,609
Deferred tax Income (Expenses) on Revaluation Surplus of PPE & Fair Value Changes of Mkt. securities		(1,167,433)	(738,828)
Total Comprehensive Income Attributable to Ordinary Shareholders		180,496,092	237,828,034
Number of Shares Used to Compute EPS		234,000,000	234,000,000
Earnings Per Share (EPS)	31	0.30	0.82

Sd/-	Sd/-	Sd/-	Sd/-	Sd/-
Chairman	Managing Director	Director	Chief Financial Officer	Company Secretary

ORION PHARMA LIMITED
Condensed Statement of Profit or Loss and Other Comprehensive Income (Unaudited)
For Three Month Period Ended 30 September 2021

Particulars	Amount In BDT		
	1 July 2021 to 30 September 2021	1 July 2020 to 30 September 2020	
Revenue from Net Sales	28.a	708,039,294	606,349,902
Cost of Goods Sold		(320,794,448)	(285,335,228)
Gross Profit		387,244,845	321,014,675
Operating Expenses		(241,696,430)	(206,459,671)
General & Administrative Expenses		(85,701,280)	(73,195,657)
Selling & Distribution Expenses		(155,995,150)	(133,264,013)
Profit from Operation		145,548,416	114,555,004
Financial Expenses	29.a	(19,404,160)	(12,890,595)
Non Operating Income/ (Loss)		432,941	539,912
Net Profit from Operation		126,577,197	102,204,322
Workers Profit Participation Fund		(6,027,486)	(4,866,872)
Net Profit before Tax		120,549,711	97,337,449
Income Tax		(28,572,950)	(25,427,598)
Current Tax (Expenses)/Income	30	(24,478,746)	(26,108,190)
Deferred Tax (Expenses)/Income		(4,094,204)	680,592
Net Profit after Tax		91,976,761	71,909,852
Share of Profit from Associates		3,189,600	2,082,100
Net Profit after Tax before Other Comprehensive Income		95,166,361	73,991,952
Other Comprehensive Income		110,203,587	46,734,965
Fair Value Gain of Marketable Securities		10,012,620	4,812,893
Fair Value Gain on Investment in Associate		101,234,889	42,305,291
Share of Other Comprehensive Income		123,511	355,609
Deferred tax Income (Expenses) on Revaluation Surplus of PPE & Fair Value Changes of Mkt. securities		(1,167,433)	(738,828)
Total Comprehensive Income attribute to Ordinary Shareholders		205,369,948	120,726,916
Number of Shares Used to Compute EPS		234,000,000	234,000,000
Earnings Per Share (EPS)	31a	0.41	0.32

Sd/-
Chairman

Sd/-
Managing Director

Sd/-
Director

Sd/-
Chief Financial Officer

Sd/-
Company Secretary

ORION PHARMA LIMITED AND ITS SUBSIDIARIES
Condensed Consolidated Statement of Changes in Equity (Unaudited)
For Three Month Period Ended 30 September 2021

Amount in BDT

Particulars	Ordinary Share Capital	Share Premium	Reserves	Retained Earnings	Total	Non controlling Interest	Total
Balance at 01 July 2021	2,340,000,000	8,016,892,026	1,904,852,372	6,400,990,484	18,662,734,883	1,411,671,307	20,074,406,190
Net Profit after Tax	-	-	-	70,292,505	70,292,505	73,657	70,366,163
Fair Value Gain /(Loss) on Investment in Associate			101,234,889	-	101,234,889	-	101,234,889
Fair Value (Loss)/Gain on Marketable Securities			10,012,620	-	10,012,620	-	10,012,620
Adjustment for sale of Mkt. Securities			4,919,681	-	4,919,681	-	4,919,681
Share of Other Comprehensive Income			123,511	-	123,511	-	123,511
Adjustment of Deferred tax on Revaluation Surplus			(1,167,433)	-	(1,167,433)	-	(1,167,433)
Depreciation on Revaluation Surplus			(2,547,844)	2,547,844	-	-	-
Balance at 30 September 2021	2,340,000,000	8,016,892,026	2,017,427,797	6,473,830,832	18,848,150,654	1,411,744,964	20,259,895,618

For Three Month Period Ended 30 September 2020

Amount in BDT

Particulars	Ordinary Share Capital	Share Premium	Reserves	Retained Earnings	Total	Non controlling Interest	Total
Balance at 01 July 2020	2,340,000,000	8,016,892,026	1,936,593,119	5,670,236,252	17,963,721,397	1,225,990,411	19,189,711,809
Net Profit after Tax	-	-	-	191,093,070	191,093,070	17,454,993	208,548,063
Fair Value Gain /(Loss) on Investment in Associate			42,305,291	-	42,305,291	-	42,305,291
Fair Value (Loss)/Gain on Marketable Securities			4,812,893	-	4,812,893	-	4,812,893
Adjustment for sale of Mkt. Securities			6,258,996	-	6,258,996	-	6,258,996
Share of Other Comprehensive Income			355,609	-	355,609	-	355,609
Adjustment of Deferred tax on Revaluation Surplus			(738,828)	-	(738,828)	-	(738,828)
Depreciation on Revaluation Surplus			(6,422,509)	6,422,509	-	-	-
Balance at 30 September 2020	2,340,000,000	8,016,892,026	1,983,164,571	5,867,751,830	18,207,808,426	1,243,445,404	19,451,253,830

Sd-
Chairman

Sd-
Managing Director

Sd-
Director

Sd-
Chief Financial Officer

Sd-
Company Secretary

ORION PHARMA LIMITED
Condensed Statement of Changes in Equity (Unaudited)
For Three Month Period Ended 30 September 2021

Particulars	Amount in BDT				
	Ordinary Share Capital	Share Premium	Reserves	Retained Earnings	Total
Balance at 01 July 2021	2,340,000,000	8,016,892,026	1,536,805,467	518,496,227	12,412,193,719
Net Profit after Tax	-	-	-	95,166,361	95,166,361
Fair Value Gain /(Loss)on Investment in Associate	-	-	101,234,889	-	101,234,889
Fair Value (Loss)/Gain on Marketable Securities	-	-	10,012,620	-	10,012,620
Adjustment for sale of Mkt. Securities	-	-	4,919,681	-	4,919,681
Share of Other Comprehensive Income	-	-	123,511	-	123,511
Adjustment of Deferred tax on Revaluation Surplus	-	-	(1,167,433)	-	(1,167,433)
Depreciation on Revaluation Surplus	-	-	(2,171,981)	2,171,981	-
Balance at 30 September 2021	2,340,000,000	8,016,892,026	1,649,756,753	615,834,569	12,622,483,348

For Three Month Period Ended 30 September 2020

Particulars	Amount in BDT				
	Ordinary Share Capital	Share Premium	Reserves	Retained Earnings	Total
Balance at 01 July 2020	2,340,000,000	8,016,892,026	1,552,679,134	457,550,939	12,367,122,098
Net Profit after Tax	-	-	-	73,991,952	73,991,952
Fair Value Gain /(Loss)on Investment in Associate	-	-	42,305,291	-	42,305,291
Fair Value (Loss)/Gain on Marketable Securities	-	-	4,812,893	-	4,812,893
Adjustment for sale of Mkt. Securities	-	-	6,258,996	-	6,258,996
Share of Other Comprehensive Income	-	-	355,609	-	355,609
Adjustment of Deferred tax on Revaluation Surplus	-	-	(738,828)	-	(738,828)
Depreciation on Revaluation Surplus	-	-	(2,455,739)	2,455,739	-
Balance at 30 September 2020	2,340,000,000	8,016,892,026	1,603,217,356	533,998,630	12,494,108,011

Sd-
Chairman

Sd-
Managing Director

Sd-
Director

Sd-
Chief Financial Officer

Sd-
Company Secretary

ORION PHARMA LIMITED AND ITS SUBSIDIARIES

Condensed Consolidated Statement of Cash Flows (Unaudited)

For Three Month Period Ended 30 September 2021

Particulars	Amount In BDT	
	1 July 2021 to 30 September 2021	1 July 2020 to 30 September 2020
A. Cash Flows from Operating Activities :		
Cash Received from Customers	1,069,704,060	1,450,293,743
Cash Paid to Suppliers	(709,704,700)	(864,244,904)
Cash Payment for Operating Expenses	5,468,502	(237,700,901)
Cash Generated from Operation	365,467,861	348,347,938
Income Taxes Paid	(8,640,953)	(6,903,290)
Net Cash Generated/(Used) from Operating Activities	356,826,908	341,444,648
B. Cash Flows from Investing Activities :		
Acquisition of Property, Plant & Equipment	(13,745,168)	(27,443,148)
Capital Work in Progress	(1,192,666,441)	(280,186,175)
Investment in Subsidiaries, Associate & Others	(184,197,960)	(940,841,522)
Interest, Dividend & Other Income	432,941	539,912
Net Cash Received/(Used) from Investing Activities	(1,390,176,629)	(1,247,930,932)
C. Cash Flows from Financing Activities :		
Long Term Loan Received/ (Repaid)	985,546,743	1,965,409,513
Short Term Loan Received/ (Repaid)	(2,620,446)	(2,011,981)
Lease obligation	(9,774,323)	(10,381,756)
Financial expenses paid	(21,134,467)	(80,332,958)
Dividend paid	(1,135,253)	(9,337,930)
Net Cash Received/(Used) from Financing Activities	950,882,254	1,863,344,889
Net Increase /(Decrease) in Cash & Cash Equivalents (A+B+C)	(82,467,466)	956,858,606
Cash & Cash Equivalents at the beginning of the period	414,994,148	1,034,178,329
Cash & Cash Equivalents at the end of the period	332,526,681	1,991,036,934
Number of Shares Used to Compute NOCFPS	234,000,000	234,000,000
Operating Cash Flow Per Share	33.1 1.52	1.46

Sd-
Chairman

Sd-
Managing Director

Sd-
Director

Sd-
Chief Financial Officer

Sd-
Company Secretary

ORION PHARMA LIMITED
Condensed Statement of Cash Flows (Unaudited)
For Three Month Period Ended 30 September 2021

Particulars	Amount In BDT	
	1 July 2021 to 30 September 2021	1 July 2020 to 30 September 2020
A. Cash Flows from Operating Activities :		
Cash Received from Customers	673,615,613	584,458,107
Cash paid to Suppliers	(300,430,278)	(230,346,227)
Cash Payment for Operating Expenses	5,468,502	(237,700,901)
Cash Generated from Operation	378,653,836	116,410,979
Income Taxes Paid	(8,640,953)	(6,903,290)
Net Cash Generated/(Used) from Operating Activities	370,012,884	109,507,689
B. Cash Flows from Investing Activities :		
Acquisition of Property, Plant & Equipment	(13,504,268)	(27,372,548)
Capital Work in Progress	(1,192,666,441)	(280,186,175)
Investment in Subsidiaries, Associate, Securities & Others	(184,197,960)	(940,841,522)
Interest, Dividend & Other Income	432,941	539,912
Net Cash Received/(Used) from Investing Activities	(1,389,935,729)	(1,247,860,332)
C. Cash Flows from Financing Activities :		
Long Term Loan Received/ (Repaid)	1,024,071,254	2,452,259,244
Short Term Loan Received/ (Repaid)	(2,537,604)	(1,767,240)
Lease obligation	(9,774,323)	(10,381,756)
Dividend paid	(1,135,253)	(9,337,930)
Interest Paid	(19,404,160)	(12,890,595)
Net Cash Received/(Used) from Financing Activities	991,219,914	2,417,881,724
Net Increase /(Decrease) in Cash & Cash Equivalents (A+B+C)	(28,702,931)	1,279,529,081
Cash & Cash Equivalents at the beginning of the period	200,606,704	630,358,211
Cash & Cash Equivalents at the end of the period	171,903,772	1,909,887,292
Number of Shares Used to Compute NOCFPS	234,000,000	234,000,000
Operating Cash Flow Per Share	33a.1 1.58	0.47

Sd-
Chairman

Sd-
Managing Director

Sd-
Director

Sd-
Chief Financial Officer

Sd-
Company Secretary

ORION PHARMA LIMITED AND ITS SUBSIDIARIES
Selected Explanatory Notes to the Condensed Consolidated Financial Statements
For Three Month Period Ended 30 September 2021 (First Quarter)

1 Reporting Entity

1.1 Background of the Entity

Orion Pharma Limited, earlier called Orion Laboratories Limited was incorporated in 1965 as a private limited company. The Company was converted into a public limited company on 24 July 2010. The registered office of the company is at 153-154, Tejgaon I/A, Dhaka-1208, Bangladesh.

The Company is listed both with Dhaka Stock Exchange Limited (DSE) and Chittagong Stock Exchange Limited (CSE) on 20 March 2013.

1.2 Nature of Business

Orion Pharma Limited is engaged in the creation and discovery, development, manufacturing and marketing of pharmaceutical products including vaccines and health-related consumer products.

1.3 Subsidiary Companies

1.3.1 Orion Power Meghnaghat Limited

Orion Power Meghnaghat Ltd. was incorporated on 30 June 2010 as a public limited company under the Companies Act, 1994 with authorized share capital of Tk. 4,000,000,000 divided into 400,000,000 Ordinary shares of Tk. 10 each. The company implemented a 100 MW HFO Power based Plant on quick rental basis in Meghnaghat, Dhaka to supply electricity to national grid with machineries and equipment supplied by Wartsila OY, Finland. Orion Pharma Ltd. holds 95% of equity share of this company directly.

1.3.2 Dutch Bangla Power & Associates Limited

Dutch Bangla Power & Associates Ltd. was incorporated on 1 July 2010 as a public limited company under the Companies Act, 1994 with authorized share capital of Tk. 1,000,000,000 divided into 100,000,000 ordinary shares of Tk. 10 each. The Company was awarded by the Government of Bangladesh and BPDB to implement 100 MW HFO Power Plant on quick rental basis in Siddhirganj, Narayanganj to supply electricity to national grid with machineries and equipment supplied by Wartsila OY, Finland. Orion Pharma Ltd. holds 67% of equity share of this Company.

1.4 Associate Company

Orion Infusion Limited

Orion Infusion Limited is a public limited company incorporated in Bangladesh on May 05, 1983 and is now operating under the banner of Orion Group. Other shareholders of the company are sponsor shareholders, foreign investors, financial institutions and general public.

The Company was listed with Dhaka Stock Exchange Limited (DSE) on 05 October 1994 and Chittagong Stock Exchange Limited (CSE) on 22 September 1996. Orion Pharma Ltd. holds 21.76 % of equity share of this company directly.

2 Basis of Preparation

2.1 Statement of Compliance

These Condensed Interim Financial Statements of the company comprised the company's and its subsidiaries (together referred to as the 'Group' and individually as 'Group entities') and the Group's interest in associates have been prepared in accordance with International Financial Reporting Standards (IFRSs) adopted by the Institute of Chartered Accountants of Bangladesh (ICAB), in particular International Accounting Standard (IAS) 34: *Interim Financial Reporting*, the Companies Act 1994, Securities and Exchange Rules 1987 and other applicable laws and regulations.

2.2 Components of the Condensed Financial Statements

According to IAS-34 'Interim Financial Reporting', these interim financial statements include the following components-

- i. Condensed Consolidated Statement of Financial Position
- ii. Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income
- iii. Condensed Consolidated Statement of Changes in Equity
- iv. Condensed Consolidated Statement of Cash Flows
- v. Selected Explanatory Notes to the Condensed Consolidated Financial Statements

2.3 Basis of Measurement

The financial statements have been prepared on historical cost basis except for certain assets which are stated either at revalued amount or fair market value.

2.4 Functional and Presentation Currency

The financial statements are prepared and presented in Bangladesh Taka (Taka/Tk./BDT), which is the company's functional and presentation currency. All amounts have been rounded off to the nearest integer.

2.5 Reporting Period

These Condensed Interim Financial Statements of the company cover three month period from 1 July 2021 to 30 September 2021.

2.6 Date of Authorization

The financial statements were authorized for issue by the Board of Directors in its meeting held on November 14, 2021 for publication.

2.7 Events after the reporting period

Information regarding subsidiary companies

For this quarter there was no such issue.

3 Accounting Policies and Methods of Computations

The accounting policies and methods of computations followed in preparing these financial statements are same as those used in the annual financial statements prepared and published for the year ended 30 June 2021.

4 Subsequent Events

No material events occurred after the reporting date, non-disclosure of which could affect the ability of the users of the financial statements to make proper evaluation and decision.

5 Acquisition of Property, Plant & Equipments of Orion Pharma Ltd. and its subsidiaries during the Period.

Discloser as per BSEC Notification No. BSEC/CMRRCD/2006-158/208/Admin/81, Dated: 20 June 2018.

SL No.	Particulars	Amount in BDT	
		30-Sep-21	30-Sep-20
i	Land & Land Development	-	7,356,900
ii	Factory & Office Building	-	5,218,137
iii	Plant & Machinery	-	10,781,791
iv	Furniture & Fixtures	7,526,224	155,000
v	Office Equipment	5,913,080	3,931,320
	Total	13,439,304	27,443,148

SL No.	Particulars	Amount in BDT	
		30-Sep-21	30-Jun-21
6. Property, plant and equipment			
Opening balance		14,219,821,108	14,930,942,237
Add: Addition during the year		13,439,304	279,081,475
		14,233,260,412	15,210,023,712
Less: Depreciation charged during the year		(95,839,686)	(990,202,605)
Written down value		14,137,420,725	14,219,821,108
6a. Property, plant and equipment			
Opening balance		7,746,013,649	7,860,572,660
Add: Addition during the year		13,198,404	275,726,745
		7,759,212,053	8,136,299,405
Less: Depreciation charged during the year		(70,871,838)	(390,285,756)
Written down value		7,688,340,215	7,746,013,649
7. Right of use assets			
Opening Balance		106,698,236	77,807,019
Add: Addition during the year		305,864	31,689,566
		107,004,100	109,496,585
Less: Disposal/ adjustment			2,798,349
		107,004,100	106,698,236
Amortization			
Opening balance		55,886,807	27,459,166
Addition during the year		6,748,920	28,427,641
		62,635,727	55,886,807
Written down value		44,368,373	50,811,429
8. Construction work in progress			
Opening balance		5,584,939,176	1,651,460,156
Add: Addition during the year		1,192,666,441	3,933,479,021
		6,777,605,617	5,584,939,176

9. Investment in subsidiaries

Name of the subsidiary company	Number of shares	Share holding (%)	Amount in BDT	
			30-Sep-21	30-Jun-21
Orion Power Meghnaghat Ltd.	95,000,000	95.00	950,000,000	950,000,000
Dutch Bangla Power & Associates L	6,700,000	67.00	67,000,000	67,000,000
Total			1,017,000,000	1,017,000,000

Investment in subsidiaries are stated at cost.

10. Investment in associate

Orion Infusion Limited

Opening balance	303,455,000	319,403,000
Add: Share of profit during the year	3,189,600	6,069,100
Less: Dividend during the year	(4,430,000)	(4,430,000)
Add: Share of other comprehensive income	123,511	647,072
Add: Fair value adjustment	101,234,889	(18,234,172)
	403,573,000	303,455,000

SL No.	Particulars	Amount in BDT	
		30-Sep-21	30-Jun-21
11. Other investment			
	Investment in marketable securities (Note 11.1)	39,283,989	29,250,714
	Investment in non-Quoted Shares (Note 11.2)	5,921,740,676	5,921,740,676
		5,961,024,665	5,950,991,390
11.1 Investment in marketable securities			
	AB Investment Limited.	22,251,030	16,564,154
	Bank Asia Securities Limited.	8,222,465	5,358,524
	LankaBangla Securities Ltd.	8,810,494	7,328,036
		39,283,989	29,250,714
11.2 Investment in non-quoted shares			
	Orion Power Khulna Limited.	500,000	500,000
	Orion Power Dhaka Limited.	500,000	500,000
	ICB Islami Bank Limited	246,000	246,000
	Orion Infrastructure Limited.	2,117,209,676	2,117,209,676
	Energon Renewable (BD) Ltd.	1,500,000	1,500,000
	Orion Power Unit - 2 Dhaka Ltd.	3,801,785,000	3,801,785,000
		5,921,740,676	5,921,740,676
11a Other investment			
	Investment in marketable securities (Note 11a.1)	39,283,989	29,250,714
	Investment in non-Quoted Shares (Note 11a.2)	2,120,240,676	2,120,240,676
		2,159,524,665	2,149,491,390
11a.1 Investment in marketable securities			
	AB Investment Limited.	22,251,030	16,564,154
	Bank Asia Securities Limited.	8,222,465	5,358,524
	LankaBangla Securities Ltd.	8,810,494	7,328,036
		39,283,989	29,250,714
11a.2 Investment in non-quoted shares			
	Orion Power Khulna Limited.	500,000	500,000
	Orion Power Dhaka Limited.	500,000	500,000
	ICB Islami Bank Limited	246,000	246,000
	Orion Infrastructure Limited.	2,117,209,676	2,117,209,676
	Orion Power Unit - 2 Dhaka Ltd.	1,785,000	1,785,000
		2,120,240,676	2,120,240,676
12. Inventories			
	Raw materials	163,593,355	153,608,779
	Packing materials	49,403,778	43,386,793
	Work-in-process	22,543,758	31,834,113
	Finished goods	71,944,923	92,875,945
	Printing Stationeries	7,572,603	8,316,971
	Promotional materials	15,474,598	14,322,674
	Spare parts	601,832,224	613,524,380
	Inventory HFO & LFO	310,157,804	406,517,746
		1,242,523,043	1,364,387,400
12.a Inventories			
	Raw materials	163,593,355	153,608,779
	Packing materials	49,403,778	43,386,793
	Work-in-process	22,543,758	31,834,113
	Finished goods	71,944,923	92,875,945
	Printing Stationeries	7,572,603	8,316,971
	Promotional materials	15,474,598	14,322,674
		330,533,014	344,345,275

SL No.	Particulars	Amount in BDT	
		30-Sep-21	30-Jun-21
13. Trade & other receivables			
Trade receivables		4,061,172,517	3,943,148,046
Other receivables (Note-13.1)		8,732,869,117	8,458,309,454
		12,794,041,634	12,401,457,500

Trade receivables are unsecured, considered good and recoverable within one year. Classification schedules as required by schedule XI of Companies Act 1994 are as follows:

Ageing of the above balance is as follows:

Below 180 days	4,061,172,517	3,943,148,046
Above 180 days	-	-
	4,061,172,517	3,943,148,046

SL. No.	Particulars	Amount in BDT	
		30-Sep-21	30-Jun-21
I	Trade receivables considered good in respect of which the company is fully	4,061,172,517	3,943,148,046
II	Trade receivables considered good in respect of which the company holds no security other than the debtor personal security	-	-
III	Trade receivables considered doubtful or bad	-	-
IV	Trade receivables due by any director or other officer of the company	-	-
V	Trade receivables due by common management	-	-
VI	The maximum amount of receivable due by any director or other officer of the	-	-
	Total	4,061,172,517	3,943,148,046

13.1 Other receivables

Claim receivables, insurance & others	6,231,818	4,709,338
Divided receivable	4,430,000	4,430,000
Interest on FDR	408,841	289,684
Other receivables	1,190,233,800	816,658,511
Current account with other related companies (Note. 13.1.1)	7,531,564,658	7,632,221,921
	8,732,869,117	8,458,309,454

13.1.1 Current account with other related companies

Noakhali Gold Food Ltd.	10,859,928	10,859,928
Orion Properties Ltd.	22,101,089	22,101,089
Orion Gas Limited	49,200,000	49,200,000
Orion Power Khulna Ltd.	986,021,913	986,021,913
Orion Power Dhaka Ltd.	2,261,945,784	2,261,945,784
Jafflong Tea Company	2,408,371	2,408,371
Orion Agro Product	240,118,758	240,118,758
Interior Accom Consortium Limited	74,838,459	74,838,459
Digital Power & Associate Ltd.	679,808,401	678,701,956
Orion Footwear Ltd.	108,662,162	108,662,162
Orion Oil & Shipping Ltd.	151,023,852	156,023,852
Orion Power Unit 2 Dhaka Ltd.	1,557,202,647	1,518,974,228
Orion Home Appliance Ltd.	117,807,496	117,848,000
Orion Hospitals Ltd.	17,700,000	17,500,000
Orion Power Rupsha Ltd.	264,322,069	264,322,069
Energon Renewable (BD) Ltd.	779,108,730	914,260,353
Orion Quaderia Textiles Limited	130,000,000	130,000,000
Orion Natural Care Ltd.	78435000	78,435,000
	7,531,564,658	7,632,221,921

SL No.	Particulars	Amount in BDT	
		30-Sep-21	30-Jun-21
13.a	Trade & other receivables		
	Trade receivables	195,450,465	161,026,784
	Other receivables (Note - 13a.1)	7,591,203,319	7,402,438,017
		7,786,653,784	7,563,464,801

Trade receivables are unsecured, considered good and recoverable within one year. Classification schedules as required by schedule XI of Companies Act 1994 are as follows:

Ageing of the above balance is as follows:

Below 180 days	195,450,465	161,026,784
Above 180 days	-	-
	195,450,465	161,026,784

SL No	Particulars	Amount in BDT	
		30-Sep-21	30-Jun-21
I	Trade receivables considered good in respect of which the company is fully	195,450,465	161,026,784
II	Trade receivables considered good in respect of which the company holds no security other than the debtor personal security		-
III	Trade receivables considered doubtful or bad		-
IV	Trade receivables due by any director or other officer of the company		-
V	Trade receivables due by common management		-
VI	The maximum amount of receivable due by any director or other officer of the		-
	Total	195,450,465	161,026,784

13a.1 Other receivables

Claim receivables, insurance & others	6,231,818	4,709,338
Divided receivable	4,430,000	4,430,000
Interest on FDR	408,841	289,684
Other receivables	1,046,433,800	726,658,511
Current account with subsidiaries (13a.1.1)	372,395,908	369,895,908
Current account with other related companies (13a.1.2)	6,161,302,952	6,296,454,575
	7,591,203,319	7,402,438,017

13a.1.1 Current account with subsidiaries

Dutch Bangla Power & Associates Limited.	372,395,908	369,895,908
	372,395,908	369,895,908

13a.1.2 Current account with other related companies

Orion Properties Ltd.	20,331,532	20,331,532
Orion Power Khulna Ltd.	986,021,913	986,021,913
Orion Power Dhaka Ltd.	2,176,293,707	2,176,293,707
Interior Accom Consortium Ltd.	107,995,459	107,995,459
Orion Agro Product Ltd.	232,265,920	232,265,920
Orion Power Unit -2 Dhaka Ltd.	1,358,708,776	1,358,708,776
Orion Power Rupsha Ltd.	186,800,000	186,800,000
Digital Power & Associates Ltd.	97,341,915	97,341,915
Orion Hospitals Ltd.	12,700,000	12,700,000
Energon Renewables (BD) Ltd.	794,408,730	929,560,353
Orion Home Appliances Ltd.	110,000,000	110,000,000
Orion Natural Care Ltd.	78,435,000	78,435,000
	6,161,302,952	6,296,454,575

SL No.	Particulars	Amount in BDT	
		30-Sep-21	30-Jun-21
14.	Advances, deposits and prepayments		
	Advances:		
	Advance income tax (Note-14.1)	175,243,941	166,583,988
	Advance imprest money	107,000	85,000
	Advance motor cycle	12,414,425	13,884,063
	Advance - car loan	1,655,269	2,230,896
	Collection advance	666,037	4,188,731
	Advance to C&F agents	25,142,022	3,864,512
	Advance office rent	4,959,884	5,560,830
	Advance against land purchase	99,814,360	34,814,360
	Advance for Impoted machinery	75,211,467	364,119,356
	Advance to employee	87,572,043	89,589,470
	Other advance	94,206	94,206
	Advance Cash Purchase	505,605	2,289,827
	Import related expenses	592,661,228	46,344,248
	Advance to Supplier	66,796,086	105,694,390
		1,142,843,573	839,343,877
	Deposits:		
	Earnest money	9,766,938	9,740,000
	Security deposit	58,765,477	54,833,244
	Bank guarantee	117,809,191	117,809,191
	L/C Margin & Balance	416,643,641	938,347,076
	Lease deposit	12,591,887	14,694,360
		615,577,134	1,135,423,871
	Prepayments:		
	Insurance premium	828,870	479,668
	Bank guranttee,commission & charge	23,677,711	43,362,532
		24,506,581	43,842,200
		1,782,927,288	2,018,609,949
14.1	Advance income tax		
	Opening balance	166,583,988	133,033,784
	Add: Addition during the year	8,659,953	33,550,204
		175,243,941	166,583,988
	Less: Adjustment of assessment for previous	-	-
	Closing balance	175,243,941	166,583,988
14.a	Advances, deposits & prepayments		
	Advances:		
	Advance income tax (Note -14a.1)	173,669,519	165,028,566
	Advance imprest money	107,000	85,000
	Motor cycle advance	12,414,425	13,884,063
	Advance - car loan	1,655,269	2,230,896
	Collection advance	666,037	4,188,731
	Advance to C&F agents	25,142,022	3,864,512
	Advance office rent	4,959,884	5,560,830
	Advance against land purchase	99,814,360	34,814,360
	Advance for machinery - BHF Bank	75,211,467	364,119,356
	Advance to Employee	86,350,012	87,353,357
	Others Advance	94,206	94,206
	Advance Cash Purchase	505,605	2,289,827
	Import related expenses	592,661,228	46,344,248
	Advance Paid to Suppliers	51,242,621	90,790,049
		1,124,493,655	820,648,001

SL No.	Particulars	Amount in BDT	
		30-Sep-21	30-Jun-21
Deposits			
	Earnest money	9,766,938	9,740,000
	Security deposit	58,765,477	54,833,244
	Lease deposit	12,134,487	14,236,960
	L/C Margin & Balance	257,125,738	778,829,173
		337,792,640	857,639,377
		1,462,286,295	1,678,287,378
14a.1 Advance income tax			
	Opening balance	165,028,566	131,716,484
	Addition during the year	8,640,953	33,312,082
	Closing balance	173,669,519	165,028,566
15. Fixed deposit with banks			
	Social Islami Bank Limited., Principal Branch, Dhaka.	9,072,469	8,961,570
	Agrani Bank Ltd.	19,305,567	14,654,784
		28,378,036	23,616,354
16. Cash & cash equivalents			
	Cash in hand (Note -16.1)	22,894,071	14,500,869
	Cash at B/O account (Note -16.2)	215,446	16,834
		23,109,517	14,517,703
	Balance with banks on account		
	Current account	271,496,949	366,528,823
	Short term deposit account	37,920,214	33,947,623
		309,417,163	400,476,446
		332,526,681	414,994,148
16.1 Cash in hand			
	Head office	19,696,387	7,678,508
	Depot office	3,197,684	6,822,361
		22,894,071	14,500,869
16.2 Cash at B/O account			
	Bank Asia Securities Limited.	26,875	-
	Jahan Securities Limited.	1,974	2,424
	LankaBangla Securities Ltd.	186,598	14,410
		215,446	16,834
16.a Cash and cash equivalents			
	Cash in hand (Note -16a.1)	9,985,218	11,028,322
	Cash at B/O account (Note -16a.2)	215,446	16,834
		10,200,664	11,045,156
	Cash at Bank:		
	Current account	123,782,894	155,613,926
	Short term deposit account	37,920,214	33,947,623
		161,703,108	189,561,548
		171,903,772	200,606,704
16a.1 Cash in hand			
	Head office - central cash & main cash	6,787,534	4,205,961
	Depot office - petty cash	3,197,684	6,822,361
		9,985,218	11,028,322

SL No.	Particulars	Amount in BDT	
		30-Sep-21	30-Jun-21
16a.2	Cash at B/O account		
	Bank Asia Securities Limited	26,875	-
	Jahan Securities Limited	1,974	2,424
	LankaBangla Securities Ltd.	186,598	14,410
		215,446	16,834

17. Share capital

Authorized capital

500,000,000 ordinary shares of Tk. 10 each

5,000,000,000 **5,000,000,000**

Issued, subscribed and paid-up capital

234,000,000 ordinary shares of Tk. 10 each

2,340,000,000 **2,340,000,000**

Shareholding position of the company

Range of Shareholding	Number of Shareholders	Number of Shares	% of holding	
			30-Sep-21	30-Jun-21
Up to 500 Shares	24,320	3,205,921	1.37%	1.24%
501 to 5,000 Shares	6,530	12,438,632	5.32%	6.06%
5001 to 10,000 Shares	1,124	8,462,596	3.62%	4.00%
10,001 to 20,000 Shares	600	8,757,029	3.74%	4.04%
20,001 to above	698	201,135,822	85.96%	84.66%
Total	33,272	234000000	100%	100%

Categories of shareholders	Number of Shareholders	Number of Shares	% of holding	
			30-Sep-21	30-Jun-21
Sponsors	5	74,841,600	31.98%	31.98%
Foreign Investor	537	2,794,654	1.19%	1.21%
Financial institutions	525	95,179,377	40.67%	37.87%
General public	32,205	61,184,369	26.15%	28.94%
Total	33,272	234000000	100%	100%

Orion Power Meghnaghat Limited	Number of Shares	Face Value	% of holding	
			30-Sep-21	30-Jun-21
Orion Pharma Limited	95,000,000	950,000,000	95.00%	95.00%
Integral Energy Limited	3,000,000	30,000,000	3.00%	3.00%
Jafflong Tea Company Limited	500,000	5,000,000	0.50%	0.50%
Mr. Mohammad Obaidul Karim	500,000	5,000,000	0.50%	0.50%
Mr. Salman Obaidul Karim	600,000	6,000,000	0.60%	0.60%
Mrs. Arzuda Karim	350,000	3,500,000	0.35%	0.35%
Haarhuis Generation B.V.	50,000	500,000	0.05%	0.05%
Total	100,000,000	1,000,000,000	100%	100%

SL No.	Particulars		Amount in BDT		
			30-Sep-21	30-Jun-21	
	Dutch Bangla Power & Associates Limited	Number of Shares	Face Value	% of holding	
				30-Sep-21	30-Jun-21
	Orion Pharma Limited	6,700,000	67,000,000	67.00%	67.00%
	Shenzhen Nanshan Power Co. Ltd.	50,000	500,000	0.50%	0.50%
	Mohammad Obaidul Karim	100,000	1,000,000	1.00%	1.00%
	Salman Obaidul Karim	3,087,500	30,875,000	30.88%	30.88%
	Orion Tea Company Ltd.	50,000	500,000	0.50%	0.50%
	Jafflong Tea Co. Ltd.	2,500	25,000	0.03%	0.03%
	Mrs. Arzuda Karim	10,000	100,000	0.10%	0.10%
	Total	10,000,000	100,000,000	100%	100%

18. Reserves

Fair value gain/(loss) on investment in associate (Note -18.1)	320,176,659	218,941,769
Fair value gain /(loss) on marketable securities (Note -18.2)	1,411,958	(12,027,113)
Share of other comprehensive income of associate (Note - 18.3)	6,518,711	6,395,201
Revaluation surplus on property, plant and equipment (Note -18.4)	1,689,320,469	1,691,542,515
	2,017,427,797	1,904,852,372

18.1 Fair value gain on investment in associate

Opening balance	218,941,770	237,175,941
Fair value gain/ (loss) during the year	101,234,889	(18,234,172)
	320,176,659	218,941,769

18.2 Fair value gain/(loss) on marketable securities

Opening balance	(12,027,113)	(22,090,059)
Adjustment of sale of marketable securities	4,919,681	5,925,574
Fair value gain/(loss) on marketable securities (Note - 18.2.1)	10,012,620	5,255,477
Transferred to deferred tax assets/(liabilities)	(1,493,230)	(1,118,105)
	1,411,958	(12,027,113)

18.2.1 Fair value gain/(loss) on marketable securities during the year

Unrealized gain/(loss) position (closing)	1,568,843	(13,363,458)
Unrealized gain/(loss) position (opening)	(13,363,458)	(24,544,509)
Total change during the year	14,932,300	11,181,051
Fair value adjustment for sale of securities (realized loss)	(4,919,681)	(5,925,574)
Unrealized gain/(loss) during the year	10,012,620	5,255,477

18.3 Share of other comprehensive income

Opening balance	6,395,201	5,748,129
Add: Addition during the year	123,511	647,072
	6,518,711	6,395,201

18.4 Revaluation surplus on property, plant & equipment

Opening balance	1,691,542,515	1,715,759,107
Adjustment during the year to retained earnings for depreciation	(2,547,844)	(25,690,036)
Adjustment of deferred tax on revaluation surplus	325,797	1,473,444
	1,689,320,469	1,691,542,515

SL No.	Particulars	Amount in BDT	
		30-Sep-21	30-Jun-21
18.a Reserve			
	Fair value gain on investment in associates (Note - 18a.1)	320,176,658	218,941,769
	Fair value gain/(loss) on marketable securities (Note - 18a.2)	1,411,959	(12,027,112)
	Share of other comprehensive income (Note - 18a.3)	6,518,711	6,395,201
	Revaluation surplus on property, plant & equipment (Note - 18a.4)	1,321,649,424	1,323,495,609
		1,649,756,753	1,536,805,467
18a.1 Fair value gain on investment in associates			
	Opening balance	218,941,769	237,175,941
	Fair value gain/(loss) during the year	101,234,889	(18,234,172)
		320,176,658	218,941,769
18a.2 Fair value gain/(loss) on marketable securities			
	Opening balance	(12,027,112)	(22,090,058)
	Adjustment of sale of marketable securities	4,919,681	5,925,574
	Fair value gain/(loss) on marketable securities D/Y (Note - 18a.2.1)	10,012,620	5,255,477
	Transferred to deferred tax assets/(liabilities)	(1,493,230)	(1,118,105)
		1,411,959	(12,027,112)
18a.2.1 Fair value gain/(loss) on marketable securities during the year			
	Unrealized gain/(loss) position (closing)	1,568,843	(13,363,458)
	Unrealized gain/(loss) position (opening)	(13,363,458)	(24,544,509)
	Fair value adjustment for sale of securities realized	(4,919,681)	(5,925,574)
	Unrealized gain/(loss) during the year	10,012,620	5,255,477
18a.3 Share of other comprehensive income			
	Opening balance	6,395,201	5,748,128
	Add: Addition during the year	123,511	647,072
		6,518,711	6,395,201
18a.4 Revaluation surplus on property, plant & equipment			
	Opening balance	1,323,495,609	1,331,845,122
	Adjustment during the year to retained earnings for depreciation	(2,171,981)	(9,822,957)
	Adjustment of deferred tax on revaluation surplus	325,797	1,473,444
		1,321,649,424	1,323,495,609
19. Retained earnings			
	Opening balance	6,400,990,484	5,670,236,252
	Net profit after tax	70,292,505	939,064,196
	Dividend for the year	-	(234,000,000)
	Adjustment for depreciation on revaluation surplus	2,547,843	25,690,036
		6,473,830,832	6,400,990,484
19.a Retained Earnings			
	Opening balance	518,496,227	457,550,939
	Net profit after tax	95,166,361	285,122,331
	Dividend for the year	-	(234,000,000)
	Adjustment for depreciation on revaluation surplus	2,171,981	9,822,957
		615,834,569	518,496,227
20. Non-controlling interest			
	Opening balance	1,411,671,307	1,225,990,411
	Share of operating profit	73,657	185,680,896
	Closing balance	1,411,744,964	1,411,671,307

SL No.	Particulars	Amount in BDT	
		30-Sep-21	30-Jun-21
21	Syndicated loan and other long term loans		
	Meridian finance & Investment Ltd.	1,599,191	2,528,812
	Phoenix Finance & Investment Ltd.	201,388,764	204,083,029
	Agrani Bank Ltd. -BMRE	3,743,800,208	3,659,628,747
	Social Islami Bank Ltd	1,712,663,618	1,550,425,073
	Term Loan -SBLC Agrani Bank Ltd	2,536,109,550	2,536,109,550
	Term Loan Capital Machinery - UPAS L/C	1,307,504,276	1,128,730,942
	AL-Arafa Islami Bank Ltd.	1,933,933,761	1,902,022,581
	ODDO BHF AG Finance	1,155,541,036	735,203,573
	Rupali Bank Ltd.	1,178,957,152	1,028,693,995
	Mashreq bank PSC	3,456,437,544	3,456,437,544
		17,227,935,100	16,203,863,846
	Less: Current portion of long term loan (Note 21.1)	(393,493,077)	(274,326,280)
		16,834,442,023	15,929,537,566
21.1	Current portion of long term loan		
	Meridian Finance & Investment Ltd.	1,599,191	2,528,812
	Phoenix Finance & Investment Ltd.	61,739,304	61,739,304
	ODDO BHF AG Finance	330,154,582	210,058,164
		393,493,077	274,326,280
21.a	Long term loan		
	Meridian Finance & Investment Ltd.	1,599,191	2,528,812
	Phoenix Finance & Investment Ltd.	201,388,764	204,083,029
	Agrani Bank Ltd. -BMRE	3,743,800,208	3,659,628,747
	Social Islami Bank Ltd	1,712,663,618	1,550,425,073
	Term Loan -SBLC Agrani Bank Ltd.	2,536,109,550	2,536,109,550
	Term Loan Capital Machinery - UPAS L/C	1,307,504,276	1,128,730,942
	AL-Arafa Islami Bank Ltd.	1,933,933,761	1,902,022,581
	ODDO BHF AG Finance	1,155,541,036	735,203,573
	Rupali Bank Ltd.	1,178,957,152	1,028,693,995
		13,771,497,556	12,747,426,302
	Less: Current portion of long term loan (Note 21.a.1)	(393,493,077)	(274,326,280)
		13,378,004,479	12,473,100,022
21.a.1	Current portion long term loan		
	Meridian Finance & Investment Ltd.	1,599,191	2,528,812
	Phoenix Finance & Investment Ltd.	61,739,304	61,739,304
	ODDO BHF AG Finance	330,154,582	210,058,164
		393,493,077	274,326,280
22	Lease obligation		
	Phoenix Finance & Investment Ltd.	18,499,976	21,836,091
	Lease obligation (Office rent)	48,039,796	54,478,004
		66,539,772	76,314,095
	Current portion of lease obligation (22.1)	(34,212,112)	(36,415,462)
		32,327,660	39,898,633
22.1	Current portion of lease obligation		
	Phoenix Finance & Investment Ltd.	15,457,560	15,457,560
	Lease obligation (Office rent)	18,754,552	20,957,902
		34,212,112	36,415,462

SL No.	Particulars	Amount in BDT	
		30-Sep-21	30-Jun-21
23	Deferred tax liability		
	Opening balance	138,284,281	142,611,072
	Adjustment for deferred tax expenses /(income) (Note-23.1)	4,094,204	(3,971,453)
	Adjustment for deferred tax on revaluation surplus (Note-23.2)	1,167,433	(355,339)
		143,545,918	138,284,281

23.1 Adjustment during the year on deferred tax on PPE

Deferred tax liability on PPE (closing)	93,019,330	88,925,125
Deferred tax liability on PPE (opening)	88,925,125	92,896,578
Deferred tax expenses/(income)	4,094,204	(3,971,453)

Particular	WDV as at 30.09.2021		Amount in BDT	
	Tax Base	Accounting Base	Deferred Tax Liability as on 30.09.2021	Deferred Tax Liability as on 30.06.2021
Written down value of property, plant and equipment	3,072,870,933	3,486,290,176	(93,019,330)	(88,925,125)

23.2 Adjustment of deferred tax on revaluation Surplus

Deferred tax liability on revaluation surplus (Closing) (Note-23.2.1)	50,526,588	49,359,155
Deferred tax liability on revaluation surplus (Opening)	49,359,155	49,714,494
Deferred tax expenses/(income)	1,167,433	(355,339)

23.2.1 Adjustment of deferred tax on revaluation surplus

Particulars	WDV as at 30.09.2021		Amount in BDT	
	Tax Base	Accounting Base	Deferred Tax Liability as on 30.09.2021	Deferred Tax Liability as on 30.06.2021
Revaluation reserved on land & land development	-	1,298,728,729	(38,961,862)	(38,961,862)
Revaluation reserved factory & office building	-	59,391,408	(8,908,711)	(9,137,140)
Revaluation reserved plant & machinery	-	16,660,872	(2,499,131)	(2,596,499)
Revaluation reserve on marketable securities	-	1,568,843	(156,884)	1,336,346
Total	-	1,376,349,851	(50,526,588)	(49,359,155)

24. Shot term loans

Cash credit (Hypo) Agrani Bank Ltd.	357,963,988	357,589,783
LTR Agrani Bank Ltd., WASA Corporate Branch	137,980,759	141,033,011
Loan against marketable securities	65,834,816	65,694,373
	561,779,563	564,317,167

25 Trade and other payables

Goods suppliers & manufacturer	4,119,397,784	4,231,207,322
Other payable	317,277,517	310,634,711
Current account with inter companies (Note -25.1)	68,624,320	59,424,320
	4,505,299,621	4,601,266,353

25.1 Current account with inter companies

Orion Capital Ltd.	18,420,000	18,420,000
Orion Power Sonargaon Ltd.	50,204,320	41,004,320
	68,624,320	59,424,320

SL No.	Particulars	Amount in BDT	
		30-Sep-21	30-Jun-21
25.a	Trade and other payables		
	Goods suppliers & manufacturer	165,134,212	212,441,775
	Other payables	140,529,348	146,780,098
		305,663,560	359,221,873
26	Employee benefits		
	Employee welfare fund (Note -26.1)	11,730,743	11,104,537
	Bangladesh workers welfare foundation (Note -26.2)	15,454,274	14,828,067
	Workers profit participation fund (Note -26.3)	76,307,002	71,297,346
		103,492,019	97,229,950
26.1	Employee welfare fund		
	Opening balance	11,104,537	6,567,966
	Add: Addition for the year	626,207	5,935,950
	Less: Payment during the year	-	(1,399,378)
		11,730,743	11,104,537
26.2	Bangladesh workers welfare foundation		
	Opening balance	14,828,067	8,892,117
	Add: Addition for the year	626,207	5,935,950
		15,454,274	14,828,067
26.3	Workers profit participation fund		
	Opening balance	71,297,346	36,404,154
	Add: Addition for the year	5,009,656	47,487,592
	Less: Payment during the year	-	(12,594,400)
		76,307,002	71,297,346
26.a	Employee benefits		
	Employee welfare fund (Note -26.a.1)	4,795,634	4,192,885
	Bangladesh workers welfare foundation (Note -26.a.2)	8,519,164	7,916,415
	Workers profit participation fund (Note -26.a.3)	20,826,119	16,004,131
		34,140,917	28,113,432
26.a.1	Employee welfare fund		
	Opening Balance	4,192,885	3,854,428
	Addition during the year	602,749	1,737,835
	Payment during the year	-	(1,399,378)
		4,795,634	4,192,885
26.a.2	Bangladesh workers welfare foundation		
	Opening balance	7,916,415	6,178,580
	Add: Addition for the year	602,749	1,737,835
		8,519,164	7,916,415
26.a.3	Workers profit participation fund		
	Opening Balance	16,004,131	14,695,849
	Addition during the year	4,821,988	13,902,682
	Payment during the year	-	(12,594,400)
		20,826,119	16,004,131

WPPF is charged @ 5% of net profit before tax as per labour law Act 2006 (Amended in 2018), whereas 80% is allocated to "Workers profit participation fund", 10% to "Employee welfare fund" and 10% to "Bangladesh workers welfare foundation".

SL No.	Particulars	Amount in BDT	
		30-Sep-21	30-Jun-21
27. Accrued expenses			
Salary and wages payable		78,672,583	74,421,103
Director remuneration payable		13,125,000	8,925,000
Depot expenses payable		1,979,031	2,660,352
Telephone & mobile bill payable		3,106,242	3,677,907
Payable for final settlement of employee		6,935,631	7,970,837
Utilities payable		6,834,523	6,449,775
Provision for income tax (Note 27.1)		287,226,886	262,748,141
Corporate governance audit fees		69,000	69,000
Statutory Audit fees		575,000	1,265,000
Interest payable on Mashreq Dubai		34,445,342	6,566,474
Retention money		3,618,657	3,618,656
Provision for gratuity		22,307,848	22,445,133
Interest payable on Phonix Finance and Investment Ltd.		546,650	795,325
Withholding VAT		20,658,068	20,206,771
Withholding tax		12,395,429	12,176,535
		492,495,888	433,996,009
27.1 Provision for income tax			
Opening balance		262,748,141	197,862,877
Add: Addition during the year		24,478,746	72,485,264
		287,226,886	270,348,141
Less: Payment/AIT adjustment during the year		-	(7,600,000)
		287,226,886	262,748,141
27.a Accrued expenses			
Salary and wages payable		57,489,826	51,709,274
Director remuneration payable		300,000	300,000
Depot expenses payable		1,979,031	2,660,352
Telephone & mobile bill payable		3,106,242	3,677,907
Payable for final settlement of employee		6,935,631	7,970,837
Utilities payable		6,834,523	6,449,775
Provision for income tax (Note - 27.a.1)		287,226,886	262,748,140
Corporate governance audit fees		69,000	69,000
Statutory Audit fees		575,000	575,000
		364,516,138	336,160,285
27.a.1 Provision for income tax			
Opening balance		262,748,140	197,862,877
Add: Addition during the year		24,478,746	72,485,264
		287,226,886	270,348,140
Less: Payment/AIT adjustment during the year		-	(7,600,000)
Closing balance		287,226,886	262,748,140

SL No.	Particulars	Amount in BDT	
		30-Sep-21	30-Sep-20
28. Revenue from net sales			
Local sales		679,040,273	540,025,788
Export sales		28,999,021	66,324,114
Revenue from power generation (Note-28.1)		479,689,237	2,322,653,538
		1,187,728,531	2,929,003,440
28.1 Revenue from power generation			
Reference rental price		71,122,581	661,533,600
Reference energy price (variable - O&M)		11,840,341	69,768,203
HFO received from OOSL & BPDB		396,726,315	1,592,710,510
Foreign exchange gain /(loss)		-	(1,358,775)
		479,689,237	2,322,653,538
28.a Revenue from net sales			
Local sales		679,040,273	540,025,788
Export sales		28,999,021	66,324,114
		708,039,294	606,349,902
29 Financial expense			
Agrani Bank Limited, Cash Credit (Hypo.)		7,982,733	7,982,695
Agrani Bank Limited, LTR		3,307,727	2,317,081
Phoenix Finance & Investments Ltd.		7,059,067	1,063,981
Meridian Finance & Investment Ltd.		36,879	472,788
Finance cost on lease obligation (Office rent)		1,034,555	1,117,255
Bank Charge ,commission & Fees		1,713,507	18,864,467
Interest on Long Term Borrowing		27,878,868	46,207,161
		49,013,336	78,025,428
29a Financial expenses			
Agrani Bank Limited, Cash Credit (Hypo.)		7,982,733	7,982,695
Agrani Bank Limited, LTR		3,307,727	2,317,081
Phoenix Finance & Investments Ltd.		7,042,266	1,000,776
Meridian Finance & Investment Ltd.		36,879	472,788
Finance cost on lease obligation (Office rent)		1,034,555	1,117,255
		19,404,160	12,890,595
30. Current tax			
Profit before tax		120,549,711	97,337,449
Add: Accounting depreciation		77,620,758	112,792,524
Less: Tax depreciation		(86,896,320)	(100,373,704)
Taxable income		111,274,149	109,756,269

Income tax provision

Particulars	Taxable Income	Taxable Amount	
		30-Sep-21	30-Sep-20
22.5% income tax on taxable profit	106,237,286	23,903,389	24,777,312
Half of 22.5% Income tax on export net profit	4,937,330	555,450	1,330,878
20% income tax on dividend received	99,533	19,907	-
Total	111,274,149	24,478,746	26,108,190

SL No.	Particulars	Amount in BDT	
		30-Sep-21	30-Sep-20
31	Earnings per share (EPS)		
	The computation is given below:		
	Net profit after tax	70,292,505	191,093,070
	Ordinary shares outstanding during the year	234,000,000	234,000,000
	Earning per share	0.30	0.82
	Orion Power Meghnaghat Ltd. and Dutch Bangla Power & Associates Ltd. are two Subsidiary Companies of Orion Pharma Limited. As per contract with Bangladesh Power Development Board (BPDB) supplying electricity to the national grid has been expired in May 2021 for Orion Power Meghnaghat Ltd. and July 2021 for Dutch Bangla Power & Associates Ltd. Accordingly revenue generation has decreased in this period in comparison to the corresponding previous period. Therefore EPS has decreased to BDT 0.30.		
	The company has applied to BPDB to extend the contract period for supplying electricity for another 5 (five) years and the renewal of contract of both power plants are under process.		
31a	Earnings per share		
	The computation is given below:		
	Net profit after tax	95,166,361	73,991,952
	Ordinary shares outstanding during the year	234,000,000	234,000,000
	Earnings per share	0.41	0.32
32.	Net Assets Value (NAV) Per Share		
	Total Assets	43,504,389,063	42,333,083,454
	Total Liabilities	24,656,238,409	23,670,348,571
	Net Assets	18,848,150,654	18,662,734,883
	No of shares	234,000,000	234,000,000
	Net Assets Value (NAV) Per Share	80.55	79.76
32a	Net Assets Value (NAV) Per Share		
	Total Assets	27,870,166,773	26,662,031,155
	Total Liabilities	15,247,683,425	14,249,837,436
	Net Assets	12,622,483,348	12,412,193,719
	No of shares	234,000,000	234,000,000
	Net Assets Value (NAV) Per Share	53.94	53.04
33.	Clause No. 5 (2) (e) of Notification No. BSEC/CMRRCD/2006-158/208/Admin/81, Dated: 20 June 2018:		
	Reconciliation of Net operating cash flow under Indirect Method:		
	Particulars	30-Sep-21	30-Sep-20
	Net profit before tax	95,984,096	231,893,558
	Workers profit participation fund	6,027,486	11,594,677
	Interest & other income	(432,941)	(539,912)
	Financial expenses	49,013,335	78,025,428
	Depreciation	102,588,606	263,303,017
	Increase/(Decrease) in inventory	121,864,358	56,190,273
	Increase/(Decrease) in receivables	(113,900,657)	(1,323,732,082)
	Increase/(Decrease) in advance deposit & prepayments	190,523,614	10,983,036
	Increase/(Decrease) in payable	(105,484,531)	936,496,937
	Increase/(Decrease) in accrued expenses	19,284,497	85,491,781
	Income taxes paid	(8,640,953)	(6,903,290)
	Foreign exchange gain/(loss)	-	(1,358,775)
	Net cash flow from operating Activities	356,826,909	341,444,648
33.1	Net operating cash flow per share	1.52	1.46

SL No.	Particulars	Amount in BDT	
		30-Sep-21	30-Sep-20
33.a	Clause No. 5 (2) (e) of Notification No. BSEC/CMRRCD/2006-158/208/Admin/81, Dated: 20 June 2018:		
	Reconciliation of Net operating cash flow under Indirect Method:		
	Particulars	30-Sep-21	30-Sep-20
	Net profit before tax	120,549,711	97,337,449
	Workers profit participation fund	6,027,486	4,866,872
	Interest & other income	(432,941)	(539,912)
	Financial expenses	19,404,160	12,890,595
	Depreciation	77,620,758	112,792,524
	Increase/(Decrease) in inventory	13,812,261	(26,521,062)
	Increase/(Decrease) in receivables	(34,423,681)	(21,891,795)
	Increase/(Decrease) in advance, deposit & prepayments	224,642,035	(50,340,698)
	Increase/(Decrease) in payable	(52,423,059)	(4,576,611)
	Increase/(Decrease) in accrued expenses	3,877,108	(7,606,382)
	Income taxes paid	(8,640,953)	(6,903,290)
	Net cash flow from operating activities	370,012,884	109,507,689
33a.1	Net operating cash flow per share	1.58	0.47

Sd/-
Chairman

Sd/-
Managing Director

Sd/-
Director

Sd/-
Chief Financial Officer

Sd/-
Company Secretary